The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)

Summary A decade after International Myeloma Working Group (IMWG) biomarkers (SLiM criteria) were introduced, this real‐world study examined their impact on diagnosis, therapy and outcomes in myeloma. Using the ANZ MRDR, 3489 newly diagnosed patients from 2013 to 2023, comprising 3232 diagnosed by CRAB (‘CRAB patients’, including 1758 who also satisfied ≥1 SLiM criteria) and 257 by SLiM (‘SLiM patients’) criteria were analysed. CRAB patients had higher R‐ISS and lower performance status, with no difference in cytogenetic risk. SLiM patients had improved progression‐free survival (PFS, 37.5 vs. 32.2 months, hazard ratio [HR] 1.31 [1.08–1.59], p = 0.003), overall survival (80.9 vs. 73.2 months, HR 1.64 [1.26–2.13], p